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Human tissue plasminogen activator holds promise for
the dissolution of coronary thrombi by intravenous
administration and withoutsystemicanticoagulation. Prior
animal experiments have been conducted only in vessels
without disease. To test the thrombolytic efficacy of re-
combinant tissue plasminogen activator in the presence
of diseased intima, an established model of atheroscle-
rosis was utilized. The aorta of 16 New Zealand white
rabbits (2 to 3 kg) was made atherosclerotic by balloon
endothelial denudation and concurrent 1% cholesterol
feeding for 8 weeks. An aged (24 hour) heterologous
(human) clot, labeled with 1-125 fibrinogen was injected
into the distal aorta and produced thrombotic occlusion.
After 1 hour of thrombosis (control period), recombi-
nant tissue plasminogen activator (100,000 IU := 1 mg
protein, n =6) or streptokinase (100,000 IU, n =5) or
saline solution (n = 5) was systemically infused over 30
minutes.
Serial blood samples, obtained to determine frac-
tional change in blood radioactivity over time, showed
In the setting of acute myocardial infarction, an ideal throm-
bolytic agent would be clot-selective. administered intra-
venously and have rapid onset of action. Studies of coronary
thrombolysis have suggested promise of myocardial salvage
or decrease in mortality, or both (1-4), but the limitations
and time delay of mobilizing a cardiac catheterization lab-
oratory for an emergency intracoronary procedure have be-
come apparent. Rijken and Collen and coworkers (5,6) ini-
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a fourfold increase of blood radioactivity after tissue
plasminogen activator and streptokinase infusion com-
pared with the control period (47,400 ± 3,300 [mean
± standard error] versus 11,800 ± 300 counts/min, p
< 0.001). Time to 50% of maximal thrombolysis was 41
± 14 minutes (± standard deviation) for tissue plas-
minogen activator versus 63 ± 16 minutes for strepto-
kinase (p < 0.01). In six of six rabbits receiving tissue
plasminogen activator and four of five rabbits receiving
streptokinase, reestablishment of distal aortic flow was
detected via the indwelling catheter within 25 minutes
of drug infusion. In the five control rabbits, reperfusion
did not occur and there was no change in blood radio-
activity over time (up to 2 hours). Gross and histologic
studies of the aortas confirmed thrombolysis and diffuse
intimal disease at the site of balloon denudation. Thus,
in atherosclerotic arteries, intravenous infusion of re-
combinant tissue plasminogen activator rapidly lysed
human thrombus and resulted in reperfusion.
(J Am Coli CardioI1985;5:85-91)
tially isolated and purified tissue type plasminogen activator
from a human melanoma cell line and have since docu-
mented its marked fibrin avidity in vitro (7), and its throm-
bolytic efficacy in animal venous models (8-10) and in
human beings (11,12). Production of tissue plasminogen
activator from melanoma cell culture fluid. however, is ex-
tremely laborious and expensive. Recently, Pennica et al.
(13) cloned and expressed the human tissue plasminogen
activator gene in Escherichia coli, and the biologic prop-
erties of melanoma and recombinant plasminogen activator
have been found to be identical (14).
Prior animal studies (8-10.15-17) using both of these
tissue type plasminogen activator preparations have been
conducted only in vessels without disease. In these exper-
iments, either a central venous segment was isolated (8-10)
or a coronary artery was acutely, mechanically traumatized
(15-17). Although such results have supported the throm-
bolytic efficacy of tissue plasminogen activator, extrapo-
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lation to human atherosclerotic, thrombotic occlusion is not
readily made. The present study was performed to determine
the thrombolytic efficacy of recombinant tissue plasminogen
activator and streptokinase in the presence of diseased intima.
Methods
Animal model. We used an established model of ath-
erosclerosis (16-21). Twenty-three New Zealand male white
rabbits (2 to 3 kg) were fed an atherogenic (I % cholesterol)
diet (19-21) for 10 weeks. After 2 weeks of such feeding,
aortic balloon endothelial denudation was performed as fol-
lows. Rabbits were anesthetized with ketamine and proma-
zine intramuscularly. A femoral artery was exposed through
a 2 cm inguinal incision and a 5F balloon catheter was
introduced into the lumen of the artery and advanced to the
level of the aortic arch over a distance of 20 em. The balloon
was inflated to 0.5 ml and the catheter was pulled back to
within 3 em of its site of introduction. This procedure was
repeated twice. The artery was ligated and the skin wound
repaired. Each rabbit received 500,000 units of benzyl pen-
icillin intramuscularly at the end of the denudation procedure.
Acutethrombus preparation. After the rabbits had re-
ceived the atherogenic diet for a mean time interval of 78
± 8 days, the thrombolytic experimental procedure was
performed. Twenty-four hours before each experiment, the
thrombus was prepared as follows. Ten ml of human blood
was aspirated into a syringe and I hour was allowed for
clot formation. All but 2 ml of clot was removed from the
syringe and the clot was transferred to a 3 ml syringe. To
this thrombus was added 0.1 ml (approximately 500,000
counts/min) of commercially available I-125-labeled human
fibrinogen (Amersham) and the clot was refrigerated at 5°C
over a 24 hour period. On the day after clot preparation,
the rabbits were maintained under deep anesthesia with ke-
tamine and promazine administered intramuscularly. A 21 g
butterfly needle was introduced into a marginal ear vein for
blood sampling and infusion of the study drug. Sodium
iodide (I ml of a 2% solution) was administered intrave-
nously to block thyroidal uptake of the isotope.
The descending aorta was exposed through a 5 em mid-
line abdominal incision and reflection of the peritoneal con-
tents. A short 5F end hole catheter was specially designed
for the experiment and introduced into the aortic lumen and
advanced 2 to 3 cm. Just distal to the catheter insertion
point, the aorta was tied to prevent anterograde flow except
through the catheter lumen (Fig. I). Catheter flow was es-
tablished and the labeled and aged clot was counted im-
mediately before injection. After baseline blood samples
were obtained, the clot was injected into the aorta and the
catheter was gently flushed with saline solution. Cessation
of flow to the distal aortic catheter was observed in each
animal as soon as the clot was injected.
Figure l. Schematic of thrombolytic experiment. The rabbit's
marginal ear vein was used for both blood sampling of 1-125
radioactivity and administration of the thrombolytic agent. The
distal aorta was cannulated and ligated distal to the catheter in-
sertion, and the aged human thrombus was injected into the aorta.
The aorticcatheterwas monitored for reestablishment of antegrade
flow.
Thrombolytic experiment. Blood samples of 1-125 ra-
dioactivity were obtained every 15 minutes for I hour before
infusion of the study drug. At the end of the hour control
period, I mg (= 100,000 IV) of recombinant tissue plas-
minogen activator (Genentech) or 100,000 IV streptokinase
(Hoechst-Roussel) or saline solution was intravenously ad-
ministered by a Harvard pump over 30 minutes. For 2 hours
from the start of the infusion, serial blood samples were
again drawn every 15 minutes. Flow to the distal aortic
indwelling catheter was monitored. After the last blood sam-
ple, the rabbit was given 2,000 V of heparin before sacrifice
with air embolism. After sacrifice, the aorta was removed
intact and cross sections of the vessel through the diseased
portion of the aorta were obtained.
Sixteen animals were successfully studied; six with re-
combinant tissue plasminogen activator, five with strepto-
kinase and five with saline solution. Of 23 rabbits success-
fully deendothelialized, 7 were excluded as follows: 4 died
from an overdose of anesthetic before study drug infusion,
I died from aortic rupture and 2 rabbits did not develop
aortic clot adherence so that cessation of the flow did not
occur.
Statistical analysis. Paired t tests were used to test for
significant differences in radioactivity release between base-
line and drug infusion periods. Analysis of variance for
repeated measurements and analysis of covariance were used
to test the hypothesis that there was a significant difference
in rate of thrombolysis (as a reflection of fractional change
in blood radioactivity). The Student's t test was used to
reject the null hypothesis that there was no difference in
time to half maximal thrombolysis between the two study
drugs. Unless otherwise noted, the values reported are mean
± standard error of the mean.
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Figure 2. Blood 1-125 radioactivity in
counts/min over time is shown for tissue
plasminogen activator (TPA). streptoki-
nase (SK) and control rabbits (saline).
There was no detectable increase in blood
radioactivity during the I hour period of
thrombotic occlusion, before adrninistra-
tion of the thrombolytic agent or for 2.5
hours after infusion in the saline-treated
rabbits. Both tissue plasminogen activator
and streptokinase led to a fourfold in-
crease in blood radioactivity, but the rate
of thrombolysis (reflected by release of
1-125 into blood) was faster for tissue
plasminogen activator than for strepto-
kinase (p = 0.03, F = 24.3 by analysis
of covariance and p < 0.0 I by ANOVA
with repeated measures). Values are
mean ± standard deviation.
Results
Thrombolysis. During the I hour control period (before
study drug infusion), there was negligible variation in the
repeated measurements of blood radioactivity for each an-
imal group (Fig. 2) . In the recombinant tissue plasminogen
activator group, 1-125 radioactivity ranged from 10,500 ±
1,000 to 11 ,500 ± 500 count s/min ; in the streptokinase
group from 11,600 ± 400 to 12,300 ± 250 counts/min
and in the control group from 10,400 ± 350 to 11,600 ±
700 count s/min. Counts obtained dur ing and 90 minutes
after study drug infusion showed no detectable increase in
the saline solution control group (minimum 11,200 ± 500
versus maximum 12,200 ± 500, P = not significant). How-
ever, recombinant tissue plasminogen activator led to a peak
fourfold increase in 1-125 blood radioactivity compared
with saline (47,400 ± 3, 300 versus 11,800 ± 300
count s/min , p < 0.00 I). Similarly, streptokinase resulted
in a 4 .2 times increase in blood radioactivity (49 ,600 ±
1,600 versus 11 ,800 ± 300 counts/min , p < O.OO\). The
peak counts of recombinant tissue plasminogen activator
compared with streptokinase were not significantly different.
The data for the 2 hour period . beginning with the onset
of drug infusion. are displayed in Figure 3. Calculating the
fractional change in blood radioactivity tends to minimize
the effects of initial differences in the prepared clot radio -
activity, which varied 21% among the 16 experiments (min-
imum 420,000 counts/min; maximum 530,000 counts/min) .
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Figure 3. The fractional increase in blood
radioactivity over time corrects for the
initial differences in the prepared clot ra-
dioactivity , which varied 21 % among the
16experiments. Both tissue plasminogen
activator (TPA) and streptokinase (SK)
led to a fourfold increase of 1-125 blood
radioactivity compared with the control
experiments. The peak in 1-125 blood ra-
dioactivity between.tissue plasminogen
activator and streptokinase is not signif-
icantly different. Values are mean ±
standard deviation.
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Table 1. Results in Three Experimental Groups
JACe Vol 5, No.1
January 1985:85-91
Experimental Group
rTPA (n = 6)
SK (n = 5)
Control (n = 5)
Thrombolysis Time
to II> Max
(minutes)
41 :!:: 14*
63 :!:: 16*
Reperfusion
6 of 6
4 of 5
oof 5
Bleeding
oof 6
3 of 5
oof 5
Residual Thrombus
5 of 6
5 of 5
5 of 5
*p < 0.01. unpaired t test; rTPA = recombinant tissue plasminogen activator: SK = streptokinase;
thrombolysis time to II> max = minutes of half-maximal 1-125 blood radioactivity.
Comparison ofrecombinant tissue plasminogen activator
with streptokinase rate of thrombolysis, reflected by the rate
of increase in blood radioactivity over time, was done by
analysis of variance for repeated measures and analysis of
covariance, both yielding the same conclusion: thrombolysis
mediated by tissue plasminogen activator was more rapid
(by covariance p = 0.03, by repeated measures p < 0.01).
Another way to demonstrate the contrast with respect to
time is to select a point and use the t test. For the time to
50% maximal thrombolysis, recombinant tissue plasmino-
gen activator was significantly shorter: 41 ± 14 minutes
(± standard deviation) versus 63 ± 16 minutes (p < 0,01).
Reperfusion and bleeding complications (Table I).
Reperfusion was determined by reestablishment of antero-
grade aortic flow to the indwelling distal catheter. This
occurred in all six rabbits treated with recombinant tissue
plasminogen activator and in four of five rabbits treated with
streptokinase but did not occur in any control animal. In
the 10 thrombolytic experiments in which reperfusion was
noted, this occurred within 25 minutes but in not less than
15 minutes. No aorta, once reperfused, was noted to reoc-
elude during the remaining 90 minutes of blood sampling
period.
Bleeding during the experiment was not apparent in any
rabbit receiving recombinant tissue plasminogen activator
or saline solution. However, two rabbits treated with strep-
tokinase had excessive wound and retroperitoneal bleeding
during the last 30 minutes of the experiment and one rabbit
had intraperitoneal bleeding profusely at 15 minutes after
the streptokinase was infused, leading to exsanguination and
early termination of the experiment.
Pathologic findings (Fig. 4 to 7). Postmortem gross and
histologic studies of each aorta were performed. An occlu-
sive, extensive thrombus was identified in each control an-
imal (Fig. 4 and 5). Small fragments of clot were demon-
strated in all but one rabbit receiving recombinant tissue
plasminogen activator and in all rabbits given streptokinase,
without appreciable difference in amount of material be-
tween these two groups.
Atherosclerosis, grossly resembling human fatty streaks
and fibrous plaques, was present in each distal aorta. Dif-
fuse, advanced, circumferential intimal involvement with
yellowish discoloration and raised plaque was noted grossly
throughout the descending thoracic and abdominal aortas,
most intense in the 6 to 8 cm proximal to iliac bifurcation
(Fig. 4).
Histologic studies revealed luminal filling with clot ma-
terial in the control rabbits in contrast to little or no thrombus
in the recombinant tissue plasminogen activator or strep-
tokinase groups (Fig. 5). There was extensive circumfer-
ential involvement of the atherosclerotic plaque noted in all
distal aortic sections of each animal; little or no uninvolved
intimal surface was present. When a clot was present his-
tologically, it appeared to adhere to intimal plaque (Fig. 6).
The atherosclerotic plaque was at least three to six times
the thickness of the underlying arterial wall (Fig. 7). Within
the typical plaque, extensive atheronecrosis was manifested
by cellular dropout and foam cells (Fig. 7). In several spec-
imens (two rabbits in each group), dissection of the media
with fragmentation of the internal elastic membrane was
observed. Particularly noteworthy was the involvement of
the media by foam cells and the presence of calcified ma-
Figure 4. Gross pathologic specimen from
a controlanimaldemonstrates thecircum-
ferential raised plaque in the distal aorta
(center), compared with normal intima
of the ascending aorta (left). The occlu-
sive thrombus is shown in the distal aorta
(right),
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Figure 5. Low power ( X 4, reduced by
15%) distal aortic histologic cross section
stained with hematoxylin-eosin . A,
Occlusive thrombus within circumferen-
tial atherosclerotic intima in a control rab-
bit. B, No residual thrombus was present
in the aorta of this rabbit treated with
tissue plasminogen activator. The similar
extent of circumferential atherosclerotic
plaque in both aortas is demonstrated .
.,
I
/ .
terial beneath the plaques. All aortas demonstrated severe .
diffuse and circumferential arteriosclerotic involvement. By
both gross examination and histologic review, there were
no appreciable intergroup differences as to the presence or
extent of the atherosclerotic lesions.
Discussion
Recombinant human plasminogen activator. This study
shows that intravenously infused recombinant human plas-
minogen activator was highly effective in achieving throm-
bolysis in atherosclerotic arteries . Although the extent of
thrombus dissolution (as reflected by peak fractional blood
Figure 6. Histologic cross section of the aorta of a control rabbit
shows thrombus adherent to the atherosclerotic intima (hematox-
ylin-eosin x 10. reduced by 49%). Residual clot fragments. ad-
herent to the intima, were identified in all thrombolytic experiments
with streptokinase and in all but one with tissue plasminogen
activator.
radioactivity) and reperfusion results for recombinant tissue
plasminogen activator and streptokinase were not different,
the rate of thrombolysis with plasminogen activator was
more rapid. Prior studies with tissue plasminogen activator
have documented its clot selectivity . Compared with strep -
tokinase and urokinase. which have no specific affinity for
fibrin, tissue plasminogen activator binds with very high
affinity (K; = 0.14 mM) (22) to the fibrin-plasminogen
complex (23). This property probabl y explains the enhanced
rapidity of plasminogen activator-mediated thrombolysis that
was found in our study. Further support of the local lysis
concept is rendered by the lack of depletion of circulating
fibrinogen. plasminogen or alpha-2-antiplasmin in all prior
studies of tissue plasminogen activator (8-12.15-17).
Thrombolysis. The time of onset of clot lysis in the
current study was noted by time to reperfusion and fractional
change of blood radioactivity. The time to half maximal
thrombolysis was 50% longer in the streptokinase-treated
rabbit s . However, the order of magnitude of our results is
in contrast with that of Bergmann et al. (15) , who found
that in a dog coronary artery thrombotic model there was a
la-fold increase in time to onset of lysis of canine thrombus
by intravenously administered streptokinase compared with
melanoma-derived tissue plasminogen activator. The dif-
ference s in the rate of thrombolysis observed between the
two studies may be the result of dissimilar animal model s.
But in addition, the role of the atherosclerotic intima in
adhering to clot may account , at least in part . for impeding
tissue plasminogen acti vator-mediated thrombolysis .
In the current study , a disparity is noted between the
short half-life of tissue plasminogen activator (2.4 minutes)
(24) and the ongoing thrombolysi s detected through blood
radioactivity . Despite only a 30 minute duration of infusion.
continued thrombolysis mediated by plasminogen activator
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B Figure 7. Histologic features of
the atherosclerotic plaque. A, The
plaque to aortic wall ratio was
typically 3:I as is shown in this
longitudinal aortic section (hema-
toxylin-eosin X 10, reduced by
30%). B, High power magnifica-
tionof atherosclerotic plaquedem-
onstrates atheronecrosis (cell drop-
out)and infiltration withfoamcells
(x 40, reduced by 30%). The in-
ternal elastic membrane (in mid-
field) separates plaquefrommedia.
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was evident for over 60 minutes. This finding is consonant
with those of Matsuo, Korninger and Collen and their col-
leagues (8-10). One possible explanation for a dispropor-
tionately long time of thrombolysis mediated by tissue plas-
minogen activator, compared with its short half-life, may
be changes in plasminogen activator binding once reper-
fusion is achieved. Once antegrade flow is reestablished,
considerably more surface area of clot is exposed to plas-
minogen activator and, thus, much lower levels of this en-
zyme may be associated with its continued ability to digest
fibrin. Alternatively, local activation may persist for a long
period of time after delivery of the agent to the clot surface.
One other explanation invokes endogenous effects, perhaps
native plasminogen activator once partial dissolution is ac-
complished. Thus, although it might be expected that in-
travenous tissue plasminogen activator could allow minute
to minute titration of fibrinolytic activity, biologic activity
(assessed by thrombolysis) may continue for some period
of time and at least up to 1 hour in the current study.
Role of atherosclerosis, The underlying atherosclerotic
lesion is a key factor in the period immediately after suc-
cessful thrombolysis. Most patients who undergo successful
coronary recanalization are left with a critical stenosis (25),
often requiring definitive intervention to prevent reocclu-
sion. In the first six patients with acute myocardial infarction
who received melanoma-derived plasminogen activator, two
developed reinfarction and three required coronary artery
bypass surgery (22). Although the atherosclerotic plaque
generated in the present study was circumferential and typ-
ically three to six times the thickness of the aortic wall, the
lesions were not greater than 50% stenotic and reocclusion
was not observed. Three factors appear to establish a pre-
disposition for reocclusion: I) underlying critical athero-
sclerosis, 2) the short half-life of tissue plasminogen acti-
vator, and 3) residual thrombus, observed in all but one of
the experiments in the current study. Should reoccltision be
a frequent clinical occurrence, the role of recombinant tissue
plasminogen activator in the future may indeed be to "bide
time" before either percutaneous transluminal angioplasty
or coronary artery grafting is performed.
In the present study we did not quantify actual throm-
bolysis. Prior studies (8-10) have used an 1-125 isotope
recovery balance to calculate percent thrombolysis. How-
ever, these calculations involve a quantitative assumption
of extravascular distribution and urine radioactivity. In stud-
ies that have utilized such an analysis, monitoring of re-
perfusion was not possible and gross or histologic studies
were not performed. The pathologic and reflow data in the
present study were well correlated with the fractional change
in blood radioactivity obtained for each experiment. The
finding of residual thrombus, albeit in small amounts, in
the recombinant tissue plasminogen activator experiments
may be a common finding when diseased atherosclerotic
vessels are subject to thrombolysis. The uniform dose of
intravenous recombinant human tissue plasminogen acti-
vator used in this study (0.375 mg/kg for 30 minutes) is
comparable with an effective therapeutic dose that has been
used in patients to achieve coronary thrombolysis (12) and
is equimolar, but not necessarily equipotent, to the strep-
tokinase dose that was utilized. It remains possible, how-
ever, that a greater dosage or a longer infusion period may
lead to more complete thrombolysis.
Implications, Recombinant tissue plasminogen activa-
tor has many properties that approach an ideal coronary
thrombolytic agent. The present study confirms its ability
to lyse human thrombus in experimentally induced athero-
sclerotic intima and points to possible advantages over strep-
tokinase with respect to time required and bleeding com-
plications. Studies are currently underway to test this prom-
ising agent in patients with acute myocardial infarction.
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